# Comparison of Efficacy and Safety Psoralen Combined With Ultraviolet A (PUVA) Vs Tofacitinib in the Treatment of Generalized Vitiligo.

> **NCT07055529** · EARLY_PHASE1 · NOT_YET_RECRUITING · sponsor: **Hayat Abad Medical Complex, Peshawar** · enrollment: 64 (estimated)

## Conditions studied

- Vitiligo, Generalized

## Interventions

- **DRUG:** Group A recieving PUVA therapy
- **DRUG:** Group B receiving Tablet Tofacitinib

## Key facts

- **NCT ID:** NCT07055529
- **Lead sponsor:** Hayat Abad Medical Complex, Peshawar
- **Sponsor class:** OTHER_GOV
- **Phase:** EARLY_PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2026-06-01
- **Primary completion:** 2026-12-31
- **Final completion:** 2026-12-31
- **Target enrollment:** 64 (ESTIMATED)
- **Last updated:** 2026-01-30


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07055529

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07055529, "Comparison of Efficacy and Safety Psoralen Combined With Ultraviolet A (PUVA) Vs Tofacitinib in the Treatment of Generalized Vitiligo.". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT07055529. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*